OPK icon

Opko Health

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 60%
Negative

Neutral
GlobeNewsWire
10 days ago
OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference
MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Piper Sandler 37th Annual Healthcare Conference, being held December 2-4, 2025 at the Lotte New York Palace Hotel in New York City. Management will be holding one-on-one meetings with investors and will be participating in a fireside discussion on Wednesday, December 3rd at 12:00 p.m. Eastern time.
OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference
Positive
Zacks Investment Research
1 month ago
OPK Q3 Earnings Beat Estimates, Sales Miss, Gross Margin Expands
OPKO Health's Q3 earnings top estimates despite lower sales. Cost cuts and product strength boost margins and operating income.
OPK Q3 Earnings Beat Estimates, Sales Miss, Gross Margin Expands
Neutral
Seeking Alpha
1 month ago
OPKO Health, Inc. (OPK) Q3 2025 Earnings Call Transcript
OPKO Health, Inc. ( OPK ) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Phillip Frost - Chairman & CEO Elias Zerhouni - President & Vice Chairman Adam Logal - Senior VP & CFO Gary Nabel - Chief Information Officer & Director Conference Call Participants Yvonne Briggs - LHA Investor Relations Maurice Raycroft - Jefferies LLC, Research Division Yi Chen - H.C. Wainwright & Co, LLC, Research Division Kevin DeGeeter - Ladenburg Thalmann & Co. Inc., Research Division Edward Tenthoff - Piper Sandler & Co., Research Division Yale Jen - Laidlaw & Company (UK) Ltd.
OPKO Health, Inc. (OPK) Q3 2025 Earnings Call Transcript
Neutral
Zacks Investment Research
1 month ago
Compared to Estimates, OPKO Health (OPK) Q3 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Compared to Estimates, OPKO Health (OPK) Q3 Earnings: A Look at Key Metrics
Positive
Zacks Investment Research
1 month ago
OPKO Health (OPK) Q3 Earnings Surpass Estimates
OPKO Health (OPK) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to earnings of $0.03 per share a year ago.
OPKO Health (OPK) Q3 Earnings Surpass Estimates
Neutral
GlobeNewsWire
1 month ago
OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results
MIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights from the third quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies.
OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results
Positive
Zacks Investment Research
1 month ago
Here's Why You Should Add OPKO Health Stock to Your Portfolio
OPK benefits from RAYALDEE momentum, strategic deals and advancing trials amid stiff competition and dependence risks.
Here's Why You Should Add OPKO Health Stock to Your Portfolio
Neutral
GlobeNewsWire
1 month ago
OPKO Health to Report Third Quarter 2025 Financial Results on October 29
MIAMI, Oct. 22, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and nine months ended September 30, 2025 after the close of the U.S. financial markets on Wednesday, October 29, 2025. OPKO's senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on October 29th beginning at 4:30 p.m. Eastern time.
OPKO Health to Report Third Quarter 2025 Financial Results on October 29
Neutral
PRNewsWire
2 months ago
Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses
BURLINGTON, N.C. and MIAMI , Sept.
Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses
Positive
Zacks Investment Research
2 months ago
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
OPK benefits from RAYALDEE momentum, strategic deals and advancing trials amid stiff competition and dependence risks.
Here's Why You Should Retain OPKO Health Stock in Your Portfolio